Nora Veszeli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6055116/publications.pdf

Version: 2024-02-01

33	537	623574	677027
papers	citations	14	22
		h-index	g-index

35	35	35	660
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	â€œNuts and Boltsâ€•of Laboratory Evaluation of Angioedema. Clinical Reviews in Allergy and Immunology, 2016, 51, 140-151.	2.9	43
2	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 901-911.	2.0	43
3	Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 132.	1.2	39
4	The role of the complement system in hereditary angioedema. Molecular Immunology, 2017, 89, 59-68.	1.0	35
5	Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema. Journal of Allergy and Clinical Immunology, 2017, 140, 1700-1703.e8.	1.5	34
6	Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients. Frontiers in Immunology, 2020, 11, 794.	2.2	29
7	Healthâ€related quality of life among children with hereditary angioedema. Pediatric Allergy and Immunology, 2017, 28, 370-376.	1.1	28
8	Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy and Asthma Proceedings, 2016, 37, 164-170.	1.0	25
9	Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet Journal of Rare Diseases, 2014, 9, 205.	1.2	24
10	Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 156.	1.2	24
11	First report of icatibant treatment in a pregnant patient with hereditary angioedema. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1026-1028.	0.6	23
12	The relationship between anxiety and quality of life in children with hereditary angioedema. Pediatric Allergy and Immunology, 2017, 28, 692-698.	1.1	20
13	A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Molecular Immunology, 2014, 57, 200-209.	1.0	19
14	Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency. Frontiers in Immunology, 2018, 9, 1721.	2.2	19
15	Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation. Frontiers in Medicine, 2020, 7, 569291.	1.2	14
16	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Frontiers in Immunology, 2021, 12, 720183.	2.2	12
17	Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. Allergy and Asthma Proceedings, 2014, 35, 255-259.	1.0	10
18	A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum. Immunology Letters, 2017, 189, 90-93.	1.1	10

#	Article	IF	Citations
19	Idiopathic Nonhistaminergic Acquired Angioedema Versus Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1205-1208.	2.0	10
20	The effect of long-term danazol treatment on haematological parameters in hereditary angioedema. Orphanet Journal of Rare Diseases, 2016, 11, 18.	1.2	9
21	Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1-inhibitor deficiency. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1791-1793.	2.7	8
22	Hereditary angioedema attack: what happens to vasoactive mediators?. International Immunopharmacology, 2020, 78, 106079.	1.7	7
23	Changes of coagulation parameters during erythema marginatum in patients with hereditary angioedema. International Immunopharmacology, 2020, 81, 106293.	1.7	7
24	Management of pregnancies in a hereditary angioedema patient after treatment with attenuated androgens since childhood. Journal of Obstetrics and Gynaecology, 2015, 35, 89-90.	0.4	6
25	Complete kinetic followâ€up of symptoms and complement parameters during a hereditary angioedema attack. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 516-520.	2.7	6
26	Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedemaâ€"A Long-Term Survey. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2379-2383.	2.0	6
27	Pathways of Neutrophil Granulocyte Activation in Hereditary Angioedema with C1 Inhibitor Deficiency. Clinical Reviews in Allergy and Immunology, 2021, 60, 383-395.	2.9	6
28	Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2015, 114, 64-65.	0.5	5
29	Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 2017, 12, 5.	1.2	5
30	Serum fetuin-A, tumor necrosis factor alpha and C-reactive protein concentrations in patients with hereditary angioedema with C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 2019, 14, 67.	1.2	3
31	Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency. International Immunopharmacology, 2020, 80, 106216.	1.7	3
32	Thyroid hormones and complement parameters in hereditary angioedema with C1-inhibitor deficiency. Annals of Allergy, Asthma and Immunology, 2016, 117, 175-179.	0.5	2
33	A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report. Frontiers in Immunology, 2021, 12, 608604.	2.2	1